Ph II Early BC Pre-Surgical Biologic Study

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Breast Cancer

Treatments: Drug: Gefitinib

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00637026

1839IL/0219

Details and patient eligibility

About

A pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with Iressa.

Enrollment: 65 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Invasive breast cancer, Aged 18 years or older, Not more than 28 days from initial diagnosis

Exclusion criteria

• Pregnant or lactating patients, Prior or current radiotherapy for breast cancer, Known allergy reaction to Iressa

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)